Metabolic Cancer Therapy 2026: Glycolysis, Mitochondria, and the Emerging Role of GLP-1 Signaling

Cancer metabolism has become one of the most intensively studied therapeutic frontiers. While cytotoxic chemotherapy targets DNA replication, metabolic therapy targets energy production, redox balance, and biosynthesis.

This article compares the mechanistic effects of:

• 2-Deoxy-D-glucose

• Metformin

• Berberine

• Ivermectin

• Mebendazole

• Fenbendazole

• GLP-1–based therapies such as Semaglutide and Tirzepatide

We will examine how each affects:

• Glycolysis

• Mitochondrial respiration

• AMPK and mTOR signaling

• Insulin and systemic glucose flux

• Tumor selectivity

Obesity and Cancer: Established Evidence

The link between obesity and cancer is well established. The International Agency for Research on Cancer concluded in 2016 that excess body fat increases the risk of at least 13 cancers (1).

Key cancers linked to obesity include:

• Colorectal

• Postmenopausal breast

• Endometrial

• Pancreatic

• Liver

Mechanisms supported by human and translational data include:

Hyperinsulinemia

Chronic elevation of insulin increases signaling through:

• Insulin receptor

• IGF-1 receptor

• PI3K–AKT–mTOR pathway

This growth signaling axis is central in many tumors (2).

Chronic Inflammation

Obesity-associated adipose tissue produces inflammatory cytokines contributing to tumor-promoting environments.

These mechanisms provide a biologically plausible basis for cancer risk reduction if metabolic dysfunction is reversed.

The Warburg Effect: Why Glycolysis Is a Cancer Target

Most cancer cells exhibit:

• Increased glucose uptake

• Upregulated GLUT1 expression

• Aerobic glycolysis (lactate production despite oxygen)

• Diversion of glycolytic intermediates into nucleotide and lipid synthesis

This metabolic reprogramming supports:

• Rapid proliferation

• Redox balance

• Biomass accumulation

Targeting glycolysis or mitochondrial function can disrupt this advantage.

1. Direct Glycolysis Blockade

2-Deoxy-D-glucose

2-DG is the most direct glycolytic inhibitor discussed here.

Mechanism:

• Glucose analog transported via GLUT

• Phosphorylated by hexokinase

• Cannot proceed further in glycolysis

• Accumulates as 2-DG-6-phosphate

• Blocks glycolytic flux

Consequences:

• Rapid ATP depletion

• AMPK activation

• ER stress

• mTOR suppression

Limitations:

• Not tumor-specific

• Affects brain and immune cells

• Narrow therapeutic window

2-DG is a substrate-level glycolysis inhibitor.

---

2. Mitochondrial Complex I Inhibitors

Metformin

Metformin primarily targets mitochondrial respiration.

Mechanism:

• Inhibits complex I

• Reduces ATP production

• Increases AMP/ATP ratio

• Activates AMPK

• Suppresses mTOR

Effect on glycolysis:

• Initially increases glycolysis as compensation

• Can induce energetic crisis in metabolically inflexible tumors

Metformin’s anticancer signal is stronger in hyperinsulinemic or insulin-resistant patients.

---

Berberine

Berberine shares similarities with metformin.

Mechanisms:

• Complex I inhibition

• AMPK activation

• mTOR suppression

• HIF-1α downregulation

• Reduced GLUT1 expression

Additional effects:

• NF-κB suppression

• ROS induction in tumor models

Berberine may suppress both mitochondrial respiration and glycolytic gene expression.

---

3. Signaling-Mediated Metabolic Suppression

Ivermectin

Ivermectin reduces oncogenic metabolic signaling.

Mechanisms:

• PI3K/AKT/mTOR inhibition

• HIF-1α suppression

• Reduced GLUT1 expression

• Increased ROS

Rather than directly inhibiting glycolysis, it suppresses the signaling pathways that drive the Warburg phenotype.

---

4. Cytoskeletal–Metabolic Disruption

Mebendazole and Fenbendazole

Both disrupt β-tubulin.

Metabolic consequences:

• Impaired GLUT transporter trafficking

• Reduced glucose uptake

• Disrupted hexokinase–mitochondrial interactions

• Indirect ATP reduction

Cancer cells are more vulnerable due to high proliferation and cytoskeletal dependence.

---

5. Systemic Metabolic Modulation: GLP-1 Receptor Agonists

Semaglutide and Tirzepatide

GLP-1 therapies do not directly inhibit glycolysis or mitochondria at the cellular level. Their anticancer relevance is systemic.

Mechanisms:

• Increase insulin secretion (glucose-dependent)

• Reduce glucagon

• Slow gastric emptying

• Reduce appetite and caloric intake

• Promote weight loss

• Improve insulin sensitivity

Cancer-Relevant Metabolic Effects:

Chronic hyperinsulinemia and insulin resistance are associated with:

• Increased IGF-1 signaling

• mTOR activation

• Enhanced tumor growth signaling

GLP-1 agonists can reduce:

• Fasting insulin levels

• Systemic glucose flux

• mTOR pathway overstimulation

Weight loss also reduces:

• Inflammatory cytokines

• Adipokines (e.g., leptin)

• Estrogen production in adipose tissue

Thus, GLP-1 agents influence cancer metabolism indirectly via systemic endocrine modulation, not direct glycolytic blockade.

Directness of Glycolysis Inhibition (Ranked)

From most direct to least direct:

1. 2-DG — direct enzymatic blockade

2. Berberine — partial glycolytic gene suppression plus mitochondrial inhibition

3. Metformin — indirect via mitochondrial ATP restriction

4. Ivermectin — upstream signaling suppression

5. Mebendazole — cytoskeletal-metabolic interference

6. Fenbendazole — similar but less validated

7. GLP-1 agonists — systemic insulin modulation only

---

Mitochondrial Targeting Strength

Strong complex I inhibition:

• Metformin

• Berberine

Moderate mitochondrial stress:

• Ivermectin

• Mebendazole

Minimal direct mitochondrial targeting:

• 2-DG

• Fenbendazole

• GLP-1 agonists

---

AMPK Activation Intensity

Strong activation:

• Metformin

• Berberine

Moderate activation:

• 2-DG (secondary to ATP drop)

Indirect/variable:

• Ivermectin

• Mebendazole

• Fenbendazole

Systemic metabolic improvement (not direct AMPK targeting in tumors):

• GLP-1 agonists

---

Tumor Selectivity

Lowest selectivity:

• 2-DG

Moderate selectivity via metabolic inflexibility:

• Metformin

• Berberine

Conditional selectivity via signaling/proliferation:

• Ivermectin

• Mebendazole

• Fenbendazole

Systemic risk-modifying agents rather than tumor-targeting drugs:

• GLP-1 receptor agonists

---

The Metabolic Stacking Framework

Potential theoretical layers:

Glycolysis blockade:

• 2-DG

Mitochondrial restriction:

• Metformin

• Berberine

Growth signaling suppression:

• Ivermectin

Structural-metabolic interference:

• Mebendazole

• Fenbendazole

Systemic insulin reduction and adiposity reduction:

• Semaglutide

• Tirzepatide

However, risks include:

• Excessive ATP depletion

• Immune suppression

• Hypoglycemia

• Gastrointestinal intolerance

• Lean mass loss with aggressive weight reduction

Clinical validation beyond metformin and GLP-1 metabolic outcomes remains limited.

---

Translational Evidence Gradient

Strongest real-world metabolic outcome data:

• GLP-1 receptor agonists (weight loss, insulin reduction)

• Metformin

Early or exploratory oncology data:

• Mebendazole

Primarily preclinical anticancer data:

• Ivermectin

• Berberine

Anecdotal with minimal oncology trials:

• Fenbendazole

Investigational metabolic inhibitor with limited clinical adoption:

• 2-DG

---

Final Perspective: Cellular vs Systemic Metabolic Therapy

Metabolic cancer therapy operates at two levels:

Cellular-Level Interventions

• 2-DG

• Metformin

• Berberine

• Ivermectin

• Mebendazole

• Fenbendazole

These act inside tumor cells to disrupt ATP production, glycolysis, or growth signaling.

Systemic-Level Interventions

• GLP-1 receptor agonists

These reduce insulin, adiposity, and systemic metabolic drivers of tumor growth.

The most biologically plausible future strategies may combine:

• Tumor-intrinsic metabolic vulnerability targeting

• Systemic endocrine normalization

• Precision biomarker selection

Metabolism in cancer is a network, not a single pathway. Successful interventions will likely require multi-node modulation with careful safety calibration.

References

1. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602

2. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928. doi:10.1038/nrc2536

3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183

4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038

5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141

6. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3

7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827

8. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271–284. doi:10.1016/j.diabres.2012.07.008

9. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831

10. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil–based chemotherapy toxicity. Lancet Oncol. 2007;8(7):629–636. doi:10.1016/S1470-2045(07)70152-9

11. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–761. doi:10.1056/NEJMoa066603

12. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–651. doi:10.1056/NEJMoa1600869